Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I–II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21)

INTRODUCTION: Relapsed and refractory B-cell acute lymphoblastic leukaemia (R/R-B-ALL) is linked to a significant relapse rate after allogeneic haematopoietic cell transplantation (allo-HCT) in children, adolescents and young adults (CAYA). No standard treatment has been established to prevent relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakaguchi, Hirotoshi, Umeda, Katsustugu, Kato, Itaru, Sakaguchi, Kimiyoshi, Hiramatsu, Hidefumi, Ishida, Hiroyuki, Yabe, Hiromasa, Goto, Hiroaki, Kawahara, Yuta, Yamashita, Yuka Iijima, Sanada, Masashi, Deguchi, Takao, Takahashi, Yoshiyuki, Saito, Akiko, Noma, Hisashi, Horibe, Keizo, Taga, Takashi, Adachi, Souichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111906/
https://www.ncbi.nlm.nih.gov/pubmed/37068890
http://dx.doi.org/10.1136/bmjopen-2022-070051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111906/
https://www.ncbi.nlm.nih.gov/pubmed/37068890
http://dx.doi.org/10.1136/bmjopen-2022-070051

Ejemplares similares